Skip to main content
main-content
Erschienen in: InFo Neurologie + Psychiatrie 7-8/2021

19.08.2021 | Multiple Sklerose | Zertifizierte Fortbildung Neurologie Zur Zeit gratis

COVID-19

Immunmodulatorische Therapien bei Multipler Sklerose in der Pandemie

verfasst von: Dr. med. Marc Pawlitzki, Univ.-Prof. Dr. med. Dr. rer. nat. Sven G. Meuth

Erschienen in: InFo Neurologie + Psychiatrie | Ausgabe 7-8/2021

zum CME-Kurs Einloggen, um Zugang zu erhalten

Auszug

Vor dem Hintergrund der anhaltenden COVID-19(Corona-Virus-Disease-19)-Pandemie besteht weiterhin eine Unsicherheit aufseiten von Patienten und Behandlern im Umgang mit Immuntherapien zur Behandlung der Multiplen Sklerose (MS). Dieser Artikel soll die aktuellen Zusammenhänge zwischen der MS-Erkrankung und dem Risiko einer COVID-19-Erkrankung beleuchten sowie praktische Handlungsempfehlungen im Umgang mit Immuntherapien liefern.
Literatur
1.
Zurück zum Zitat Portaccio E, Fonderico M, Hemmer B, et al. Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey. Mult Scler 2021:13524585211005339 Portaccio E, Fonderico M, Hemmer B, et al. Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey. Mult Scler 2021:13524585211005339
2.
Zurück zum Zitat Vogel AC, Schmidt H, Loud S, McBurney R, Mateen FJ. Impact of the COVID-19 pandemic on the health care of >1,000 People living with multiple sclerosis: A cross-sectional study. Mult Scler Relat Disord 2020; 46:102512 Vogel AC, Schmidt H, Loud S, McBurney R, Mateen FJ. Impact of the COVID-19 pandemic on the health care of >1,000 People living with multiple sclerosis: A cross-sectional study. Mult Scler Relat Disord 2020; 46:102512
3.
Zurück zum Zitat Sormani MP, De Rossi N, Schiavetti I, et al. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Ann Neurol 2021 Sormani MP, De Rossi N, Schiavetti I, et al. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Ann Neurol 2021
4.
Zurück zum Zitat Ciampi E, Uribe-San-Martin R, Carcamo C. COVID-19 pandemic: The experience of a multiple sclerosis centre in Chile. Mult Scler Relat Disord 2020;42:102204 Ciampi E, Uribe-San-Martin R, Carcamo C. COVID-19 pandemic: The experience of a multiple sclerosis centre in Chile. Mult Scler Relat Disord 2020;42:102204
5.
Zurück zum Zitat Fan M, Qiu W, Bu B, et al. Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm 2020; Fan M, Qiu W, Bu B, et al. Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm 2020;
6.
Zurück zum Zitat Louapre C, Collongues N, Stankoff B, et al. Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. JAMA Neurol 2020;77:1079-1088 Louapre C, Collongues N, Stankoff B, et al. Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. JAMA Neurol 2020;77:1079-1088
7.
Zurück zum Zitat Mohn N, Konen FF, Pul R, et al. Experience in Multiple Sclerosis Patients with COVID-19 and Disease-Modifying Therapies: A Review of 873 Published Cases. J Clin Med 2020;9. Mohn N, Konen FF, Pul R, et al. Experience in Multiple Sclerosis Patients with COVID-19 and Disease-Modifying Therapies: A Review of 873 Published Cases. J Clin Med 2020;9.
8.
Zurück zum Zitat Pawlitzki M, Zettl UK, Ruck T, Rolfes L, Hartung HP, Meuth SG. Merits and culprits of immunotherapies for neurological diseases in times of COVID-19. EBioMedicine 2020;56:102822 Pawlitzki M, Zettl UK, Ruck T, Rolfes L, Hartung HP, Meuth SG. Merits and culprits of immunotherapies for neurological diseases in times of COVID-19. EBioMedicine 2020;56:102822
9.
Zurück zum Zitat Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med 2017;376:209-220 Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med 2017;376:209-220
10.
Zurück zum Zitat Zettl UK, Hecker M, Aktas O, Wagner T, Rommer PS. Interferon beta-1a and beta-1b for patients with multiple sclerosis: updates to current knowledge. Expert Rev Clin Immunol 2018;14:137-153 Zettl UK, Hecker M, Aktas O, Wagner T, Rommer PS. Interferon beta-1a and beta-1b for patients with multiple sclerosis: updates to current knowledge. Expert Rev Clin Immunol 2018;14:137-153
11.
Zurück zum Zitat Reder AT, Centonze D, Naylor ML, et al. COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies. CNS Drugs 2021;35:317-330 Reder AT, Centonze D, Naylor ML, et al. COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies. CNS Drugs 2021;35:317-330
12.
Zurück zum Zitat Consortium WHOST, Pan H, Peto R, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med 2021;384:497-511 Consortium WHOST, Pan H, Peto R, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med 2021;384:497-511
13.
Zurück zum Zitat Longbrake EE, Naismith RT, Parks BJ, Wu GF, Cross AH. Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance. Mult Scler J Exp Transl Clin 2015;1 Longbrake EE, Naismith RT, Parks BJ, Wu GF, Cross AH. Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance. Mult Scler J Exp Transl Clin 2015;1
14.
Zurück zum Zitat Morales FS, Koralnik IJ, Gautam S, Samaan S, Sloane JA. Risk factors for lymphopenia in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate. J Neurol 2020;267:125-131 Morales FS, Koralnik IJ, Gautam S, Samaan S, Sloane JA. Risk factors for lymphopenia in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate. J Neurol 2020;267:125-131
15.
Zurück zum Zitat Mantero V, Abate L, Basilico P, et al. COVID-19 in dimethyl fumarate-treated patients with multiple sclerosis. J Neurol 2020 Mantero V, Abate L, Basilico P, et al. COVID-19 in dimethyl fumarate-treated patients with multiple sclerosis. J Neurol 2020
16.
Zurück zum Zitat Capone F, Motolese F, Luce T, Rossi M, Magliozzi A, Di Lazzaro V. COVID-19 in teriflunomide-treated patients with multiple sclerosis: A case report and literature review. Mult Scler Relat Disord 2021;48:102734 Capone F, Motolese F, Luce T, Rossi M, Magliozzi A, Di Lazzaro V. COVID-19 in teriflunomide-treated patients with multiple sclerosis: A case report and literature review. Mult Scler Relat Disord 2021;48:102734
17.
Zurück zum Zitat Jack D, Damian D, Nolting A, Galazka A. COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update. Mult Scler Relat Disord 2021;51:102929 Jack D, Damian D, Nolting A, Galazka A. COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update. Mult Scler Relat Disord 2021;51:102929
18.
Zurück zum Zitat Sorensen PS, Sellebjerg F. Pulsed immune reconstitution therapy in multiple sclerosis. Ther Adv Neurol Disord 2019;12:1756286419836913 Sorensen PS, Sellebjerg F. Pulsed immune reconstitution therapy in multiple sclerosis. Ther Adv Neurol Disord 2019;12:1756286419836913
19.
Zurück zum Zitat Pfeuffer S, Rolfes L, Hackert J, et al. Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres. Mult Scler 2021:13524585211012227 Pfeuffer S, Rolfes L, Hackert J, et al. Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres. Mult Scler 2021:13524585211012227
20.
Zurück zum Zitat Roy R, Alotaibi AA, Freedman MS. Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis. CNS Drugs 2021;35:385-402 Roy R, Alotaibi AA, Freedman MS. Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis. CNS Drugs 2021;35:385-402
21.
Zurück zum Zitat Tasat DR, Yakisich JS. Rationale for the use of sphingosine analogues in COVID-19 patients. Clin Med (Lond) 2021;21:e84-e87 Tasat DR, Yakisich JS. Rationale for the use of sphingosine analogues in COVID-19 patients. Clin Med (Lond) 2021;21:e84-e87
22.
Zurück zum Zitat Pantazou V, Pot C, Du Pasquier R, Le Goff G, Theaudin M. Recurrence of disease activity after fingolimod discontinuation in older patients previously stable on treatment. Mult Scler Relat Disord 2021;51:102918 Pantazou V, Pot C, Du Pasquier R, Le Goff G, Theaudin M. Recurrence of disease activity after fingolimod discontinuation in older patients previously stable on treatment. Mult Scler Relat Disord 2021;51:102918
23.
Zurück zum Zitat Ruck T, Bittner S, Wiendl H, Meuth SG. Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond. Int J Mol Sci 2015;16:16414-16439 Ruck T, Bittner S, Wiendl H, Meuth SG. Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond. Int J Mol Sci 2015;16:16414-16439
24.
Zurück zum Zitat Hartung HP, Mares J, Barnett MH. Alemtuzumab: Rare serious adverse events of a high-efficacy drug. Mult Scler 2020;26:737-740 Hartung HP, Mares J, Barnett MH. Alemtuzumab: Rare serious adverse events of a high-efficacy drug. Mult Scler 2020;26:737-740
25.
Zurück zum Zitat Mohn N, Pfeuffer S, Ruck T, et al. Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF. Neurol Neuroimmunol Neuroinflamm 2020;7 Mohn N, Pfeuffer S, Ruck T, et al. Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF. Neurol Neuroimmunol Neuroinflamm 2020;7
26.
Zurück zum Zitat Lunemann JD, Ruck T, Muraro PA, Bar-Or A, Wiendl H. Immune reconstitution therapies: concepts for durable remission in multiple sclerosis. Nat Rev Neurol 2020;16:56-62 Lunemann JD, Ruck T, Muraro PA, Bar-Or A, Wiendl H. Immune reconstitution therapies: concepts for durable remission in multiple sclerosis. Nat Rev Neurol 2020;16:56-62
27.
Zurück zum Zitat Ellrichmann G, Bolz J, Peschke M, et al. Peripheral CD19(+) B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders. J Neurol 2019;266:57-67 Ellrichmann G, Bolz J, Peschke M, et al. Peripheral CD19(+) B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders. J Neurol 2019;266:57-67
28.
Zurück zum Zitat Trojano M, Ramio-Torrenta L, Grimaldi LM, et al. A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis. Mult Scler 2021:13524585211003020 Trojano M, Ramio-Torrenta L, Grimaldi LM, et al. A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis. Mult Scler 2021:13524585211003020
29.
Zurück zum Zitat Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002;360:2018-2025 Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002;360:2018-2025
30.
Zurück zum Zitat Otero-Romero S, Ascherio A, Lebrun-Frenay C. Vaccinations in multiple sclerosis patients receiving disease-modifying drugs. Curr Opin Neurol 2021;34:322-328 Otero-Romero S, Ascherio A, Lebrun-Frenay C. Vaccinations in multiple sclerosis patients receiving disease-modifying drugs. Curr Opin Neurol 2021;34:322-328
31.
Zurück zum Zitat Nguyen J, Hardigan P, Kesselman MM, Demory Beckler M. Immunogenicity of The Influenza Vaccine in Multiple Sclerosis Patients: A Systematic Review and Meta-Analysis. Mult Scler Relat Disord 2021;48:102698 Nguyen J, Hardigan P, Kesselman MM, Demory Beckler M. Immunogenicity of The Influenza Vaccine in Multiple Sclerosis Patients: A Systematic Review and Meta-Analysis. Mult Scler Relat Disord 2021;48:102698
32.
Zurück zum Zitat Achiron A, Dolev M, Menascu S, et al. COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021. Mult Scler 2021;27:864-870 Achiron A, Dolev M, Menascu S, et al. COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021. Mult Scler 2021;27:864-870
33.
Zurück zum Zitat Kelly H, Sokola B, Abboud H. Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients. J Neuroimmunol 2021;356:577599 Kelly H, Sokola B, Abboud H. Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients. J Neuroimmunol 2021;356:577599
34.
Zurück zum Zitat Ciotti JR, Valtcheva MV, Cross AH. Effects of MS disease-modifying therapies on responses to vaccinations: A review. Mult Scler Relat Disord 2020;45:102439 Ciotti JR, Valtcheva MV, Cross AH. Effects of MS disease-modifying therapies on responses to vaccinations: A review. Mult Scler Relat Disord 2020;45:102439
35.
Zurück zum Zitat von Hehn C, Howard J, Liu S, et al. Immune response to vaccines is maintained in patients treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm 2018;5:e409 von Hehn C, Howard J, Liu S, et al. Immune response to vaccines is maintained in patients treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm 2018;5:e409
36.
Zurück zum Zitat Bar-Or A, Wiendl H, Miller B, et al. Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens. Neurol Neuroimmunol Neuroinflamm 2015;2:e70 Bar-Or A, Wiendl H, Miller B, et al. Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens. Neurol Neuroimmunol Neuroinflamm 2015;2:e70
37.
Zurück zum Zitat Kappos L, Mehling M, Arroyo R, et al. Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis. Neurology 2015;84:872-879 Kappos L, Mehling M, Arroyo R, et al. Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis. Neurology 2015;84:872-879
38.
Zurück zum Zitat Mehling M, Hilbert P, Fritz S, et al. Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients. Ann Neurol 2011;69:408-413 Mehling M, Hilbert P, Fritz S, et al. Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients. Ann Neurol 2011;69:408-413
39.
Zurück zum Zitat Olberg HK, Eide GE, Cox RJ, et al. Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy. Eur J Neurol 2018;25:527-534 Olberg HK, Eide GE, Cox RJ, et al. Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy. Eur J Neurol 2018;25:527-534
40.
Zurück zum Zitat Achiron A, Mandel M, Dreyer-Alster S, et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Therapeutic Advances in Neurological Disorders 2021;14:17562864211012835 Achiron A, Mandel M, Dreyer-Alster S, et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Therapeutic Advances in Neurological Disorders 2021;14:17562864211012835
41.
Zurück zum Zitat Centonze D, Rocca MA, Gasperini C, et al. Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus. J Neurol 2021 Centonze D, Rocca MA, Gasperini C, et al. Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus. J Neurol 2021
42.
Zurück zum Zitat Nazi I, Kelton JG, Larche M, et al. The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood 2013;122:1946-1953 Nazi I, Kelton JG, Larche M, et al. The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood 2013;122:1946-1953
43.
Zurück zum Zitat Kim W, Kim SH, Huh SY, et al. Reduced antibody formation after influenza vaccination in patients with neuromyelitis optica spectrum disorder treated with rituximab. Eur J Neurol 2013;20:975-980 Kim W, Kim SH, Huh SY, et al. Reduced antibody formation after influenza vaccination in patients with neuromyelitis optica spectrum disorder treated with rituximab. Eur J Neurol 2013;20:975-980
44.
Zurück zum Zitat Baker D, Roberts CAK, Pryce G, et al. COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. Clin Exp Immunol 2020;202:149-161 Baker D, Roberts CAK, Pryce G, et al. COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. Clin Exp Immunol 2020;202:149-161
45.
Zurück zum Zitat Bar-Or A, Calkwood JC, Chognot C, et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study. Neurology 2020;95:e1999-e2008 Bar-Or A, Calkwood JC, Chognot C, et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study. Neurology 2020;95:e1999-e2008
46.
Zurück zum Zitat Kaufman M, Pardo G, Rossman H, Sweetser MT, Forrestal F, Duda P. Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis. J Neurol Sci 2014;341:22-27 Kaufman M, Pardo G, Rossman H, Sweetser MT, Forrestal F, Duda P. Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis. J Neurol Sci 2014;341:22-27
47.
Zurück zum Zitat Vagberg M, Kumlin U, Svenningsson A. Humoral immune response to influenza vaccine in natalizumab-treated MS patients. Neurol Res 2012;34:730-733 Vagberg M, Kumlin U, Svenningsson A. Humoral immune response to influenza vaccine in natalizumab-treated MS patients. Neurol Res 2012;34:730-733
48.
Zurück zum Zitat Olberg HK, Cox RJ, Nostbakken JK, Aarseth JH, Vedeler CA, Myhr KM. Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study. Mult Scler 2014;20:1074-1080 Olberg HK, Cox RJ, Nostbakken JK, Aarseth JH, Vedeler CA, Myhr KM. Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study. Mult Scler 2014;20:1074-1080
Metadaten
Titel
COVID-19
Immunmodulatorische Therapien bei Multipler Sklerose in der Pandemie
verfasst von
Dr. med. Marc Pawlitzki
Univ.-Prof. Dr. med. Dr. rer. nat. Sven G. Meuth
Publikationsdatum
19.08.2021
Verlag
Springer Medizin
Erschienen in
InFo Neurologie + Psychiatrie / Ausgabe 7-8/2021
Print ISSN: 1437-062X
Elektronische ISSN: 2195-5166
DOI
https://doi.org/10.1007/s15005-021-2009-2